AAN Presentation

2025 AAN Presentation:

ALTITUDE-AD: Use of Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease

File Type: pdf
File Size: 2 MB
Categories: 2025
Tags: AAN, ALTITUDE-AD, Presentation, pTau217, sabirnetug, TwentyTwentyFive